Press Releases

Recent Press Releases

Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431
Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program
Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION’ Clinical Trial of CRV431 in NASH
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a ‘AMBITION’ Clinical Trial of CRV431 for the Treatment of Advanced NASH
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431
Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021
Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering
Hepion Pharmaceuticals Announces Pricing of Public Offering
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a ‘AMBITION’ Clinical Trial for Treatment of Advanced NASH
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a ‘AMBITION’ Clinical Trial for Treatment of Advanced NASH
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a ‘AMBITION’ Clinical Trial for NASH
Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease
Hepion Announces Closing of Public Offering of Common Stock
Hepion Pharmaceuticals Prices Public Offering
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation of Phase 2a ‘AMBITION’ Clinical Trial for Treatment of Advanced NASH
Hepion Pharmaceuticals to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium
Hepion Pharmaceuticals to Present at The Liver Meeting Digital Experience(TM) 2020
Hepion Pharmaceuticals to Present on Therapeutic Approaches to COVID-19 and NASH at Two Virtual Conferences on October 28 and 29, 2020
Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development & Announces Creation of Clinical Pharmacology Analytics Team
Hepion Pharmaceuticals to Present at H.C. Wainwright’s 4th Annual NASH Virtual Investor Conference
Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases
Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431
Hepion Pharmaceuticals to Present CRV431 Preclinical Data at the 2020 Digital International Liver Congress(TM)
Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431’s Antiviral Properties
Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial
Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431
Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Kidney Fibrosis
Hepion Pharmaceuticals Welcomes Industry Veteran and Drug Development Expert, Dr. Peter Wijngaard, to its Board of Directors
Hepion Pharmaceuticals Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
Hepion Pharmaceuticals’ CRV431 the First Cyclophilin Inhibitor to Advance to Phase 2 Trial for NASH Fibrosis
Hepion Pharmaceuticals’ CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study
Anti-Fibrotic Activity of Hepion Pharmaceuticals’ CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases
Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study
Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference
Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs
Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019
Hepion Pharmaceuticals Announces Canadian Research Team’s Academic Appointments
Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
Hepion Pharmaceuticals’ CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease
Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019
Hepion Pharmaceuticals’ CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH
Hepion Pharmaceuticals to Present on CRV431 at the 3rd Annual NASH Summit
Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431’s Potential as a Treatment for Chronic Liver Diseases
World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director
Hepion Pharmaceuticals Strengthens Management Team with Three Key Promotions
Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference
Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
Hepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceutical Sciences at University of Alberta